Patents by Inventor Yong-Jin Wu

Yong-Jin Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220119388
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 18, 2021
    Publication date: April 21, 2022
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Patent number: 11294518
    Abstract: The present disclosure relates to the field of touch technology, and provides a touch display module including a substrate, a transparent conductive layer, a moisture barrier layer, and a display element. The transparent conductive layer is disposed on the substrate. The moisture barrier layer extends laterally on the transparent conductive layer and covers the transparent conductive layer, and the moisture barrier layer includes inorganic materials. The display element is disposed on the moisture barrier layer. The touch display module of the present disclosure can avoid or slow down the water vapor/humidity intrusion from the environment, thereby meeting the specification requirements for improving product reliability test.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: April 5, 2022
    Assignee: TPK Advanced Solutions Inc.
    Inventors: Qi Bin Liu, Kuolung Fang, You Zhi She, Ya Ting Hsu, Bao Lin Liu, Yong Jin Wu, Pei Qin Xu
  • Publication number: 20220083170
    Abstract: The present disclosure relates to the field of touch technology, and provides a touch display module including a substrate, a transparent conductive layer, a moisture barrier layer, and a display element. The transparent conductive layer is disposed on the substrate. The moisture barrier layer extends laterally on the transparent conductive layer and covers the transparent conductive layer, and the moisture barrier layer includes inorganic materials. The display element is disposed on the moisture barrier layer. The touch display module of the present disclosure can avoid or slow down the water vapor/humidity intrusion from the environment, thereby meeting the specification requirements for improving product reliability test.
    Type: Application
    Filed: September 15, 2020
    Publication date: March 17, 2022
    Inventors: Qi Bin Liu, Kuolung Fang, You Zhi She, Ya Ting Hsu, Bao Lin Liu, Yong Jin Wu, Pei Qin Xu
  • Patent number: 10836758
    Abstract: The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 17, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yong-Jin Wu, Jason M. Guernon
  • Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20200048240
    Abstract: The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 13, 2020
    Inventors: Yong-Jin WU, Jason M. Guernon
  • Patent number: 10526323
    Abstract: Compounds, including those of the following formula: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 7, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Joanne Bronson, Yong-Jin Wu, Jason Guernon
  • Patent number: 10227343
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 12, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins, Joanne Bronson, Yong-Jin Wu, Kyle Emmitte, Joe Panarese, Darren W. Engers, Julie Engers
  • Publication number: 20180022746
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Joanne Bronson, Yong-Jin Wu, Jason Guernon
  • Publication number: 20180022745
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins, Joanne Bronson, Yong-Jin Wu, Kyle Emmitte, Joe Panarese, Darren W. Engers, Julie Engers
  • Patent number: 9475784
    Abstract: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein R1 and R2 are independently hydrogen, or —CH3; or R1 and R2 can join together in a ring by adding —(CH2)4—; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, —C?OC1-4alkyl, —SO2C1-4alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is —NHCO— or is a single bond; and L and Z
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: October 25, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong-Jin Wu, Jason M. Guernon
  • Publication number: 20150336975
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Publication number: 20150329506
    Abstract: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or —CH3; or R1 and R2 can join together in a ring by adding —(CH2)4—; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, —C?OC1-4 alkyl, —SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is —NHCO—, or is a single bond; an
    Type: Application
    Filed: December 19, 2012
    Publication date: November 19, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yong-Jin Wu, Jason M. Guernon
  • Publication number: 20150152089
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Patent number: 8710061
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Patent number: 8637525
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: January 28, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Patent number: 8637523
    Abstract: Compounds of the formula (I) are provided, including pharmaceutically acceptable salts thereof: which modulate ?-amyloid peptide (?-AP) production, and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: January 28, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Lorin A. Thompson, III, Yong-Jin Wu, Yunhui Zhang
  • Patent number: 8604024
    Abstract: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein X is selected from the group of CH2, O, and NR2; m=0 or 1; R1 at each instance is selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is a bond, —NHCO—, —NH—, or L and Z together can be absent; Z is a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, haloC1-4 alkoxy, 4-methoxyphenyl, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; R2 is selected from the group of hydrogen, benzyl, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, acetyl, and methanesulfonyl; and R3, R4 and R5 are independently selected from hydrogen or C1-4alkyl.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: December 10, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lorin A. Thompson, III, Jianliang Shi, Yong-Jin Wu, Lawrence R. Marcin, Ramkumar Rajamani, Mendi A. Higgins
  • Patent number: 8598161
    Abstract: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein R1, R2, R3, R4, R5, and R6 are independently hydrogen, C1-C6 alkyl or C1-C6 cycloalkyl; Y and Z are independently a C6-C10-aryl group or a 5-10 membered heterocyclic group, wherein each Y and Z group can be optionally substituted with from 0-3 substituents selected from halogen, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, OH, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is either a bond or is —NHCO—; L and Z together can be absent; and m is 1, 2 or 3.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Yong-Jin Wu
  • Patent number: 8486952
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: July 16, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev